Corticosteroids

Classification (by GLUCOCORTICOID:MINERALOCORTICOID ratio — organizing principle)

Short-acting, HIGH mineralocorticoid: hydrocortisone(cortisol itself), cortisone — physiological replacement(adrenal insufficiency, mineralocorticoid activity genuinely wanted). Intermediate, MINIMAL mineralocorticoid: prednisolone, methylprednisolone — standard anti-inflammatory/immunosuppressive workhorses. Long-acting, NEGLIGIBLE mineralocorticoid: dexamethasone, betamethasone — highest glucocorticoid potency/longest duration, used where fluid retention specifically unwanted(cerebral oedema). Pure/near-pure mineralocorticoid: fludrocortisone — replace mineralocorticoid activity specifically(adrenal insufficiency adjunct, some orthostatic hypotension).

Mechanism

Diffuse across membrane → bind cytoplasmic glucocorticoid receptor(± mineralocorticoid receptor) → nuclear translocation → binds glucocorticoid response elements → alters gene transcription. GENOMIC mechanism(needs new protein synthesis) → DELAYED onset(hours, not immediate like antihistamine) — contrast with faster-acting anti-inflammatories.

Anti-inflammatory actions(4 distinct downstream effects, not one vague action): (1) ↑Lipocortin-1/annexin A1 → inhibits phospholipase A2 → cuts off ENTIRE eicosanoid cascade(both COX+LOX branches) at source — BROADER than NSAIDs’ COX-only block = why steroids more broadly anti-inflammatory than NSAIDs. (2) ↓pro-inflammatory cytokine transcription(IL-1, IL-2, IL-6, TNF-α). (3) ↓leukocyte migration/adhesion molecule expression. (4) Lymphocyte effects: REDISTRIBUTION out of blood into lymphoid tissue(transient LYMPHOPENIA after dose = redistribution, NOT destruction — specific lab finding) + genuine ↓proliferation/cytokine production with sustained use → basis of immunosuppressive role(autoimmune, transplant).

Metabolic actions(“glucocorticoid” namesake): ↑hepatic gluconeogenesis+glycogen synthesis, ↓peripheral glucose uptake(genuine insulin-antagonist at tissue level) → hyperglycaemia, steroid-induced diabetes(chronic). + protein catabolism(muscle wasting) + central fat redistribution(Cushingoid).

HPA Axis & Adrenal Suppression (HIGH-YIELD)

Exogenous steroid → negative feedback → suppresses CRH/ACTH → chronic understimulation → adrenal cortical atrophy. TWO consequences:

Abrupt withdrawal after prolonged therapy → ACUTE adrenal insufficiency risk(atrophied adrenal can’t immediately resume output; HPA recovery = weeks-months) → requires GRADUAL TAPER, never abrupt stop + STRESS-DOSE coverage during acute illness/surgery(normal stress-cortisol surge can’t occur from suppressed axis).
Degree/reversibility depends on DOSE+DURATION — SHORT courses(<~2-3wk) at typical dose generally DON’T need taper; longer courses/high cumulative dose DO — specific practical threshold, not blanket rule.

Adverse Effects (systemic, long-term — all trace to mechanism above)

Hyperglycaemia/diabetes(metabolic action) · osteoporosis(↓osteoblast activity + ↓intestinal Ca2+ absorption, dose/duration-related — consider bone-protective co-therapy) · peptic ulceration(modest alone, SIGNIFICANT +NSAIDs — synergistic-risk combination) · immunosuppression(↑infection risk incl LATENT TB reactivation → screen before long-term therapy) · Cushingoid features(central obesity, moon facies, buffalo hump, striae — exogenous mirror of endogenous Cushing’s) · cataracts+glaucoma(mechanism incompletely understood, well-documented chronic risk) · growth suppression in children(weighed vs disease control need, e.g. chronic asthma) · psychiatric effects(mood elevation, occasionally psychosis at higher dose).

Clinical Relevance

Glucocorticoid:mineralocorticoid ratio = deliberate matching exercise, not “pick a steroid”: hydrocortisone’s retained mineralocorticoid activity = right for adrenal insufficiency; dexamethasone’s negligible mineralocorticoid activity = right for cerebral oedema(fluid retention would worsen the problem). HPA-suppression logic correctly predicts WHICH patients need taper(long-course/high-dose) vs don’t(short-course) — genuinely practical distinction, not blanket rule for every prescription regardless of duration.

Classification (by Glucocorticoid:Mineralocorticoid Potency Ratio)

The relative glucocorticoid-versus-mineralocorticoid potency of a given corticosteroid is the organizing fact determining its clinical role — not simply “how strong” a steroid is overall, but which of the two receptor activities dominates:

Short-acting, high mineralocorticoid activity: hydrocortisone (cortisol itself), cortisone — used for physiological replacement in adrenal insufficiency, where mineralocorticoid activity is genuinely wanted alongside glucocorticoid replacement.
Intermediate-acting, minimal mineralocorticoid activity: prednisolone, methylprednisolone — the standard workhorses for anti-inflammatory/immunosuppressive therapy where mineralocorticoid effects (sodium retention, hypertension) are unwanted.
Long-acting, negligible mineralocorticoid activity: dexamethasone, betamethasone — highest glucocorticoid potency and longest duration, used where prolonged, potent anti-inflammatory action is needed and mineralocorticoid effect is specifically undesirable (e.g. cerebral oedema, where fluid retention would be counterproductive).
Pure/near-pure mineralocorticoid: fludrocortisone — used specifically to replace mineralocorticoid activity (e.g. in adrenal insufficiency where hydrocortisone’s own mineralocorticoid activity is judged insufficient, or in some forms of orthostatic hypotension).

Mechanism of Action

Corticosteroids diffuse across the cell membrane and bind cytoplasmic glucocorticoid receptors (and, for agents with mineralocorticoid activity, mineralocorticoid receptors), and the activated receptor-hormone complex translocates to the nucleus, where it binds glucocorticoid response elements to alter gene transcription — this genomic mechanism, requiring new protein synthesis, explains corticosteroids’ characteristically delayed onset of anti-inflammatory action (hours, not the immediate effect of, say, an antihistamine), a specific, examined pharmacodynamic point worth contrasting with faster-acting anti-inflammatory drugs.

Anti-inflammatory/immunosuppressive actions, worth understanding as several genuinely distinct downstream effects of the same transcriptional mechanism rather than one vague “anti-inflammatory” action: (1) induction of lipocortin-1 (annexin A1), which inhibits phospholipase A2, cutting off the entire eicosanoid cascade (both prostaglandins via COX and leukotrienes via lipoxygenase) at its source — a broader, more upstream anti-inflammatory action than NSAIDs’ COX-only blockade, the specific mechanistic reason corticosteroids are more broadly anti-inflammatory than NSAIDs; (2) suppression of pro-inflammatory cytokine gene transcription (IL-1, IL-2, IL-6, TNF-α, and others), reducing the inflammatory signalling cascade broadly; (3) reduced leukocyte migration/adhesion molecule expression, limiting inflammatory cell trafficking to tissue; (4) lymphocyte effects — redistribution of circulating lymphocytes out of blood into lymphoid tissue (producing a measurable, transient lymphopenia after a dose, a specific, sometimes-examined laboratory finding that reflects redistribution rather than destruction) alongside genuine suppression of lymphocyte proliferation/cytokine production with sustained use, the basis for corticosteroids’ immunosuppressive role in autoimmune disease and transplant rejection prevention.

Metabolic actions (the physiological basis of “glucocorticoid” as a name): promotes hepatic gluconeogenesis and glycogen synthesis, while reducing peripheral glucose uptake (a genuine insulin-antagonist effect at the tissue level) — producing hyperglycaemia and, with chronic use, contributing to steroid-induced diabetes, the mechanistic basis of one of the most clinically significant chronic adverse effects (below). Also promotes protein catabolism (muscle wasting with chronic use) and redistributes fat centrally (the characteristic Cushingoid fat distribution).

The HPA Axis and Adrenal Suppression — A Specific, High-Yield Concept

Exogenous corticosteroid administration, via normal negative feedback, suppresses endogenous CRH/ACTH release from the hypothalamus/pituitary, which over time causes adrenal cortical atrophy from chronic understimulation — this is the mechanistic basis for two distinct, both frequently-examined clinical consequences:

Abrupt withdrawal after prolonged therapy risks acute adrenal insufficiency (the atrophied adrenal cannot immediately resume normal cortisol output even once the exogenous steroid is stopped, and the hypothalamic-pituitary drive to stimulate it, though eventually recovering, does so gradually over weeks to months) — the specific reason long-term corticosteroid therapy requires a gradual taper, never abrupt cessation, and the reason patients on chronic therapy need stress-dose steroid coverage during acute illness/surgery (the body’s normal stress-response cortisol surge cannot occur from a suppressed axis, so it must be supplied exogenously).
The degree and reversibility of suppression depends on dose and duration — short courses (under ~2–3 weeks) at typical doses generally do not require tapering, while longer courses or high cumulative doses do — a specific, practically important clinical threshold worth knowing rather than assuming every corticosteroid course needs tapering regardless of duration.

Adverse Effects — Systemic, Long-Term Use

Essentially all trace back to the mechanisms above, worth learning as consequences of a known mechanism rather than an unconnected list: hyperglycaemia/diabetes (metabolic action above), osteoporosis (direct inhibition of osteoblast activity plus reduced intestinal calcium absorption, a genuinely significant, dose/duration-related risk requiring bone-protective co-therapy consideration in long-term users), peptic ulceration (a genuinely debated, likely modest independent risk that becomes clearly significant when combined with NSAIDs — an important, specifically-examined synergistic-risk combination rather than either drug alone), immunosuppression (increased infection risk, including reactivation of latent infections like tuberculosis — screening before starting long-term therapy is standard practice for exactly this reason), Cushingoid features (central obesity, moon facies, buffalo hump, striae — the exogenous mirror of endogenous Cushing’s syndrome), cataracts and glaucoma (a specific, mechanism-incompletely-understood but well-documented ocular risk with chronic use), growth suppression in children (a specific paediatric concern, weighed against disease control needs in conditions like chronic asthma), and psychiatric effects (mood elevation, or occasionally psychosis, at higher doses — a specific, examined, sometimes underappreciated adverse effect).

Clinical Relevance

The glucocorticoid:mineralocorticoid potency ratio is what makes corticosteroid selection a deliberate matching exercise rather than “pick a steroid”: hydrocortisone’s retained mineralocorticoid activity makes it right for adrenal insufficiency replacement specifically, while dexamethasone’s negligible mineralocorticoid activity makes it right for cerebral oedema specifically (where fluid retention would worsen the very problem being treated) — and the HPA-axis-suppression logic is what correctly predicts which patients need a taper (long-course/high-dose) versus which don’t (short-course), a genuinely practical distinction this topic exists to teach rather than a blanket rule to apply to every corticosteroid prescription regardless of duration.

Glucocorticoid:mineralocorticoid potency ratio spectrum (hydrocortisone → prednisolone → dexamethasone → fludrocortisone) mapped to clinical use case.
HPA axis negative feedback loop showing exogenous steroid suppressing CRH/ACTH and causing adrenal atrophy, explaining the taper/stress-dose requirement.